The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not all comers.
ApexOnco Front Page
Recent articles
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Could a new ADC project distract attention away from evorpacept?
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
